Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 507 entries
Sorted by: Best Match Show Resources per page
Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-beta.

International journal of oncology

Singh R, Bucana C, Llansa N, Sanchez R, Fidler I.
PMID: 21544408
Int J Oncol. 1996 Apr;8(4):649-56. doi: 10.3892/ijo.8.4.649.

The production of basic fibroblast growth factor (bFGF) by human renal cell carcinoma (HRCC) is associated with induction of angiogenesis. Incubation of HRCC cells with human interferon alpha (IFN-alpha) or interferon beta (IFN-beta) downregulates the expression of bFGF and,...

Cite
Singh R, Bucana C, Llansa N, et al. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-beta. Int J Oncol. 1996;8(4):649-56doi: 10.3892/ijo.8.4.649.
Singh, R., Bucana, C., Llansa, N., Sanchez, R., & Fidler, I. (1996). Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-beta. International journal of oncology, 8(4), 649-56. https://doi.org/10.3892/ijo.8.4.649
Singh, R, et al. "Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-beta." International journal of oncology vol. 8,4 (1996): 649-56. doi: https://doi.org/10.3892/ijo.8.4.649
Singh R, Bucana C, Llansa N, Sanchez R, Fidler I. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-beta. Int J Oncol. 1996 Apr;8(4):649-56. doi: 10.3892/ijo.8.4.649. PMID: 21544408.
Copy Download .nbib Format: NLM
The role of glatiramer acetate in the early treatment of multiple sclerosis.

Neuropsychiatric disease and treatment

Brandes DW.
PMID: 20628633
Neuropsychiatr Dis Treat. 2010 Jun 24;6:329-36. doi: 10.2147/ndt.s5898.

The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The...

Cite
Brandes DW. The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2010;6:329-36doi: 10.2147/ndt.s5898.
Brandes, D. W. (2010). The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatric disease and treatment, 6329-36. https://doi.org/10.2147/ndt.s5898
Brandes, David W. "The role of glatiramer acetate in the early treatment of multiple sclerosis." Neuropsychiatric disease and treatment vol. 6 (2010): 329-36. doi: https://doi.org/10.2147/ndt.s5898
Brandes DW. The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2010 Jun 24;6:329-36. doi: 10.2147/ndt.s5898. PMID: 20628633; PMCID: PMC2898171.
Copy Download .nbib Format: NLM
Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.

Expert opinion on pharmacotherapy

Doggrell SA.
PMID: 20408749
Expert Opin Pharmacother. 2010 Jul;11(10):1777-81. doi: 10.1517/14656566.2010.481671.

Most people with multiple sclerosis (MS) have the relapsing-remitting type. The objective was to evaluate two clinical trials of fingolimod in relapsing MS. FREEDOMS (FTY720 Research Evaluation Effects of Daily Oral therapy in Multiple Sclerosis), a Phase III placebo-controlled...

Cite
Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. Expert Opin Pharmacother. 2010;11(10):1777-81doi: 10.1517/14656566.2010.481671.
Doggrell, S. A. (2010). Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. Expert opinion on pharmacotherapy, 11(10), 1777-81. https://doi.org/10.1517/14656566.2010.481671
Doggrell, Sheila A. "Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15." Expert opinion on pharmacotherapy vol. 11,10 (2010): 1777-81. doi: https://doi.org/10.1517/14656566.2010.481671
Doggrell SA. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15. Expert Opin Pharmacother. 2010 Jul;11(10):1777-81. doi: 10.1517/14656566.2010.481671. PMID: 20408749.
Copy Download .nbib Format: NLM
AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata.

Evidence-based complementary and alternative medicine : eCAM

Shen T, Yang WS, Yi YS, Sung GH, Rhee MH, Poo H, Kim MY, Kim KW, Kim JH, Cho JY.
PMID: 23840248
Evid Based Complement Alternat Med. 2013;2013:210736. doi: 10.1155/2013/210736. Epub 2013 Jun 06.

Andrographolide (AG) is an abundant component of plants of the genus Andrographis and has a number of beneficial properties including neuroprotective, anticancer, anti-inflammatory, and antidiabetic effects. Despite numerous pharmacological studies, the precise mechanism of AG is still ambiguous. Thus,...

Cite
Shen T, Yang WS, Yi YS, et al. AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata. Evid Based Complement Alternat Med. 2013;2013:210736doi: 10.1155/2013/210736.
Shen, T., Yang, W. S., Yi, Y. S., Sung, G. H., Rhee, M. H., Poo, H., Kim, M. Y., Kim, K. W., Kim, J. H., & Cho, J. Y. (2013). AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata. Evidence-based complementary and alternative medicine : eCAM, 2013210736. https://doi.org/10.1155/2013/210736
Shen, Ting, et al. "AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata." Evidence-based complementary and alternative medicine : eCAM vol. 2013 (2013): 210736. doi: https://doi.org/10.1155/2013/210736
Shen T, Yang WS, Yi YS, Sung GH, Rhee MH, Poo H, Kim MY, Kim KW, Kim JH, Cho JY. AP-1/IRF-3 Targeted Anti-Inflammatory Activity of Andrographolide Isolated from Andrographis paniculata. Evid Based Complement Alternat Med. 2013;2013:210736. doi: 10.1155/2013/210736. Epub 2013 Jun 06. PMID: 23840248; PMCID: PMC3690257.
Copy Download .nbib Format: NLM
Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load.

Hepatology research : the official journal of the Japan Society of Hepatology

Okushin H, Yamamoto T, Kishida H, Morii K, Uesaka K.
PMID: 23745758
Hepatol Res. 2014 Jul;44(7):728-34. doi: 10.1111/hepr.12182. Epub 2013 Jul 11.

AIM: Initial hepatitis C virus (HCV) RNA reduction was investigated as a potential index for sustained virological response (SVR) in the treatment of interferon (IFN)-β followed by peginterferon plus ribavirin (PEG IFN/RBV).METHODS: The treatment course was retrospectively analyzed in...

Cite
Okushin H, Yamamoto T, Kishida H, et al. Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load. Hepatol Res. 2013;44(7):728-34doi: 10.1111/hepr.12182.
Okushin, H., Yamamoto, T., Kishida, H., Morii, K., & Uesaka, K. (2014). Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load. Hepatology research : the official journal of the Japan Society of Hepatology, 44(7), 728-34. https://doi.org/10.1111/hepr.12182
Okushin, Hiroaki, et al. "Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load." Hepatology research : the official journal of the Japan Society of Hepatology vol. 44,7 (2014): 728-34. doi: https://doi.org/10.1111/hepr.12182
Okushin H, Yamamoto T, Kishida H, Morii K, Uesaka K. Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load. Hepatol Res. 2014 Jul;44(7):728-34. doi: 10.1111/hepr.12182. Epub 2013 Jul 11. PMID: 23745758.
Copy Download .nbib Format: NLM
In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106.

EJNMMI research

Takano A, Piehl F, Hillert J, Varrone A, Nag S, Gulyás B, Stenkrona P, Villemagne VL, Rowe CC, Macdonell R, Tawil NA, Kucinski T, Zimmermann T, Schultze-Mosgau M, Thiele A, Hoffmann A, Halldin C.
PMID: 23618062
EJNMMI Res. 2013 Apr 24;3(1):30. doi: 10.1186/2191-219X-3-30.

BACKGROUND: The activation of microglia, in general, and the upregulation of the translocator protein (18 kDa) (TSPO) system, in particular, are key features of neuroinflammation, of which the in vivo visualization and quantitative assessment are still challenging due to...

Cite
Takano A, Piehl F, Hillert J, et al. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Res. 2013;3(1):30doi: 10.1186/2191-219X-3-30.
Takano, A., Piehl, F., Hillert, J., Varrone, A., Nag, S., Gulyás, B., Stenkrona, P., Villemagne, V. L., Rowe, C. C., Macdonell, R., Tawil, N. A., Kucinski, T., Zimmermann, T., Schultze-Mosgau, M., Thiele, A., Hoffmann, A., & Halldin, C. (2013). In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI research, 3(1), 30. https://doi.org/10.1186/2191-219X-3-30
Takano, Akihiro, et al. "In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106." EJNMMI research vol. 3,1 (2013): 30. doi: https://doi.org/10.1186/2191-219X-3-30
Takano A, Piehl F, Hillert J, Varrone A, Nag S, Gulyás B, Stenkrona P, Villemagne VL, Rowe CC, Macdonell R, Tawil NA, Kucinski T, Zimmermann T, Schultze-Mosgau M, Thiele A, Hoffmann A, Halldin C. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Res. 2013 Apr 24;3(1):30. doi: 10.1186/2191-219X-3-30. PMID: 23618062; PMCID: PMC3640965.
Copy Download .nbib Format: NLM
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis.

Iranian journal of neurology

Baghbanian SM, Sahraian MA.
PMID: 30886680
Iran J Neurol. 2018 Jul 06;17(3):129-136.

Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β...

Cite
Baghbanian SM, Sahraian MA. Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis. Iran J Neurol. 2018;17(3):129-136
Baghbanian, S. M., & Sahraian, M. A. (2018). Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis. Iranian journal of neurology, 17(3), 129-136.
Baghbanian, Seyed Mohammad, and Sahraian, Mohammad Ali. "Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis." Iranian journal of neurology vol. 17,3 (2018): 129-136.
Baghbanian SM, Sahraian MA. Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis. Iran J Neurol. 2018 Jul 06;17(3):129-136. PMID: 30886680; PMCID: PMC6420690.
Copy Download .nbib Format: NLM
Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta.

Frontiers in neurology

Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C.
PMID: 28729851
Front Neurol. 2017 Jul 06;8:305. doi: 10.3389/fneur.2017.00305. eCollection 2017.

OBJECTIVE: To develop and validate a method for the detection of binding anti-drug antibodies (ADAs) against interferon beta (IFN-β) in human serum as part of a European initiative (ABIRISK) aimed at the prediction and analysis of clinical relevance of...

Cite
Ingenhoven K, Kramer D, Jensen PE, et al. Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. Front Neurol. 2017;8:305doi: 10.3389/fneur.2017.00305.
Ingenhoven, K., Kramer, D., Jensen, P. E., Hermanrud, C., Ryner, M., Deisenhammer, F., Pallardy, M., Menge, T., Hartung, H. P., Kieseier, B. C., Bertotti, E., Creeke, P., Fogdell-Hahn, A., & Warnke, C. (2017). Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. Frontiers in neurology, 8305. https://doi.org/10.3389/fneur.2017.00305
Ingenhoven, Kathleen, et al. "Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta." Frontiers in neurology vol. 8 (2017): 305. doi: https://doi.org/10.3389/fneur.2017.00305
Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C. Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. Front Neurol. 2017 Jul 06;8:305. doi: 10.3389/fneur.2017.00305. eCollection 2017. PMID: 28729851; PMCID: PMC5498465.
Copy Download .nbib Format: NLM
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.

Neurology and therapy

Boster A, Nicholas J, Wu N, Yeh WS, Fay M, Edwards M, Huang MY, Lee A.
PMID: 28211024
Neurol Ther. 2017 Jun;6(1):91-102. doi: 10.1007/s40120-017-0064-x. Epub 2017 Feb 16.

INTRODUCTION: Limited data are available on the real-world effectiveness of newer oral disease-modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to retrospectively compare the real-world effectiveness of dimethyl fumarate (DMF), fingolimod, teriflunomide, and injectable DMTs...

Cite
Boster A, Nicholas J, Wu N, et al. Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurol Ther. 2017;6(1):91-102doi: 10.1007/s40120-017-0064-x.
Boster, A., Nicholas, J., Wu, N., Yeh, W. S., Fay, M., Edwards, M., Huang, M. Y., & Lee, A. (2017). Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurology and therapy, 6(1), 91-102. https://doi.org/10.1007/s40120-017-0064-x
Boster, Aaron, et al. "Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database." Neurology and therapy vol. 6,1 (2017): 91-102. doi: https://doi.org/10.1007/s40120-017-0064-x
Boster A, Nicholas J, Wu N, Yeh WS, Fay M, Edwards M, Huang MY, Lee A. Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurol Ther. 2017 Jun;6(1):91-102. doi: 10.1007/s40120-017-0064-x. Epub 2017 Feb 16. PMID: 28211024; PMCID: PMC5447557.
Copy Download .nbib Format: NLM
Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis.

Frontiers in medicine

Dimopoulou D, Dimosiari A, Mandala E, Dimitroulas T, Garyfallos A.
PMID: 28791286
Front Med (Lausanne). 2017 Jul 24;4:89. doi: 10.3389/fmed.2017.00089. eCollection 2017.

Secondary thrombotic microangiopathies are associated with several underlying conditions, with most of them being resolved after the treatment of background disease. Thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathy presenting with anemia, thrombocytopenia, and neurological deficits, occurring most often...

Cite
Dimopoulou D, Dimosiari A, Mandala E, et al. Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis. Front Med (Lausanne). 2017;4:89doi: 10.3389/fmed.2017.00089.
Dimopoulou, D., Dimosiari, A., Mandala, E., Dimitroulas, T., & Garyfallos, A. (2017). Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis. Frontiers in medicine, 489. https://doi.org/10.3389/fmed.2017.00089
Dimopoulou, Despoina, et al. "Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis." Frontiers in medicine vol. 4 (2017): 89. doi: https://doi.org/10.3389/fmed.2017.00089
Dimopoulou D, Dimosiari A, Mandala E, Dimitroulas T, Garyfallos A. Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis. Front Med (Lausanne). 2017 Jul 24;4:89. doi: 10.3389/fmed.2017.00089. eCollection 2017. PMID: 28791286; PMCID: PMC5522843.
Copy Download .nbib Format: NLM
Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report.

Iranian journal of neurology

Etemadifar M, Sabeti F, Salari M.
PMID: 30210736
Iran J Neurol. 2018 Apr 04;17(2):91-94.

No abstract available.

Cite
Etemadifar M, Sabeti F, Salari M. Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report. Iran J Neurol. 2018;17(2):91-94
Etemadifar, M., Sabeti, F., & Salari, M. (2018). Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report. Iranian journal of neurology, 17(2), 91-94.
Etemadifar, Masoud, et al. "Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report." Iranian journal of neurology vol. 17,2 (2018): 91-94.
Etemadifar M, Sabeti F, Salari M. Interferon beta-1b-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in a patient treated for multiple sclerosis: A case report. Iran J Neurol. 2018 Apr 04;17(2):91-94. PMID: 30210736; PMCID: PMC6131335.
Copy Download .nbib Format: NLM
Management of Multiple Sclerosis in the Breastfeeding Mother.

Multiple sclerosis international

Almas S, Vance J, Baker T, Hale T.
PMID: 26966579
Mult Scler Int. 2016;2016:6527458. doi: 10.1155/2016/6527458. Epub 2016 Feb 04.

Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months...

Cite
Almas S, Vance J, Baker T, et al. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int. 2016;2016:6527458doi: 10.1155/2016/6527458.
Almas, S., Vance, J., Baker, T., & Hale, T. (2016). Management of Multiple Sclerosis in the Breastfeeding Mother. Multiple sclerosis international, 20166527458. https://doi.org/10.1155/2016/6527458
Almas, Saneea, et al. "Management of Multiple Sclerosis in the Breastfeeding Mother." Multiple sclerosis international vol. 2016 (2016): 6527458. doi: https://doi.org/10.1155/2016/6527458
Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int. 2016;2016:6527458. doi: 10.1155/2016/6527458. Epub 2016 Feb 04. PMID: 26966579; PMCID: PMC4757692.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 507 entries